Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.

@article{Rai2017MidodrineAT,
  title={Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.},
  author={Nitish Rai and Baljinder Singh and Akash Ranjan Singh and Rajesh Vijayvergiya and Navneet Sharma and Ashish Bhalla and Virendra Singh},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2017},
  volume={37 3},
  pages={406-414}
}
BACKGROUND Splanchnic arterial vasodilatation and subsequent sodium and water retention play an important role in cirrhotic ascites. Midodrine and tolvaptan have been used separately in these patients. However, there are no reports on the use of combination of midodrine and tolvaptan in the control of ascites. The aim of this study was to evaluate the safety and efficacy of midodrine, tolvaptan and their combination in control of refractory or recurrent ascites in cirrhotics. METHODS Fifty… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
2 Citations
35 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in patients with cirrhosis and hyponatremia

  • P Ginès, F Wong, H Watson
  • Hepatology
  • 2008
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…